A

Alexion

Global biopharmaceuticals focusing on rare diseases

Global Pricing & Access Lead - Rare Neurology

Full-TimePosted on 10/20/2026Deadline 11/4/26
No salary listed
Expert
Bachelor's, PharmD, PhD
Barcelona, Spain
HybridThree days in the office and two days working from home per week.
Business & StrategyCorporate Strategy

About the job

Requirements
  • A relevant graduate degree, such as a PhD, PharmD, Biomedical Sciences, business, or economics qualification.
  • More than 6 years of relevant drug development and/or commercialization experience within the pharmaceutical or medical industry.
  • Highly specialized rare disease and/or Neurology market access experience.
  • Knowledge of the needs and expectations of national and regional payers, insurers, and commercial customers in strategic markets.
  • Ability to communicate effectively and translate science into a compelling payer value story for leadership and other stakeholders, including close collaboration with local market access colleagues and the Commercial Launch Excellence function.
  • Experience developing evidence-based innovative value solutions, for example through working with local payers in the EU or commercial customers in the US.
  • Demonstrated leadership, initiative, and consistent delivery of high-quality work in rare-disease evidence contexts involving greater uncertainty and competition.
Responsibilities
  • Lead and drive cross-functional development of a clear, differentiated value proposition for NMOSD while influencing without authority and navigating complex organizational systems.
  • Collaborate with cross-functional teams to incorporate evidence-generation plans and real-world evidence effectively, reduce payer uncertainty, optimize patient access, and secure timely country input on endpoints and evidence plans in priority target countries.
  • Support the GMMA Commercial team in advancing NMOSD lifecycle management through governance milestones focused on market-access potential, evidence, and target product profile requirements.
  • Lead development of global market-access and pricing strategies and support their implementation with country access representatives.
  • Lead assessment of pricing and reimbursement risks and opportunities and implement corresponding mitigation actions for Neurology.
  • Create and roll out strategic value, access, and pricing communication tools and materials for NMOSD to support local pricing and reimbursement submissions and negotiations, including pricing frameworks, negotiation strategies, and toolkits aligned with the enterprise-wide launch framework.
  • Lead updates to the global reimbursement dossier for NMOSD and cross-functional market-access readiness plans for Neurology in collaboration with key countries and HEOR, Medical, and Commercial support functions.
  • Represent the GVAP perspective and strategy across cross-functional teams, including the Global Value Sub-Team and Global Launch Team, and provide updates and guidance to local teams.
  • Own the monthly Neurology payer working group to share current evidence and promote best-practice sharing across countries.
  • Understand and incorporate the patient perspective on the disease and recommend strategies that support the patient voice in key payer negotiations.
  • Support development of the Neurology pricing strategy.
  • Conduct payer and value assessments to identify market-specific pricing and reimbursement drivers and barriers, develop differentiated value propositions, and inform evidence-generation plans, regulatory strategy, and development decisions.
  • For top EU Neurology markets, lead and co-create market-level pricing and reimbursement strategies and support submissions and negotiations to drive positive outcomes.
  • Review pricing and reimbursement cases submitted by markets and support markets in maintaining value while unlocking local access in partnership with country access representatives and relevant GVAP teams.
  • Provide strategic input on access and pricing assumptions to enable accurate, market-driven LTP assumptions.
  • Communicate with GMMA senior leadership and other stakeholders on Neurology launches and NMOSD lifecycle-management pricing and reimbursement strategy.
Desired Qualifications
  • Knowledge and experience in key cost-effectiveness markets, such as the UK, Canada, and the Nordics.

About the company

Alexion focuses on discovering, developing, and selling therapies for rare and ultra-rare diseases by targeting the complement system. Its drugs, such as Soliris and Ultomiris, inhibit C5 to block inflammatory cascades, while Strensiq and Kanuma treat metabolic and lysosomal disorders. The company combines in-house R&D with acquisitions to expand its portfolio and leverages AstraZeneca’s global scale to reach patients. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to international markets at premium pricing.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1992

Get referred to Alexion

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AstraZeneca's July 2026 half-year revenue rose 9%, driven partly by Alexion's rare-disease growth.
  • Ultomiris gained FDA Priority Review on June 15, 2026 for IgAN, with Q4 2026 decision.
  • Koselugo's November 2025 adult NF1 approval and ALXN2220 phase 3 expand the pipeline.

What critics are saying

  • EmblemHealth's April 2025 Soliris antitrust suit targets patent settlements and biosimilar delays.
  • Soliris faces biosimilar erosion after March 2025, while Ultomiris still depends on C5-franchise switching.
  • Ultomiris carries meningococcal boxed warnings; a single fatal infection can trigger litigation and prescribing pullback.

What makes Alexion unique

  • Alexion pioneered complement biology, turning C5 inhibition into approved medicines since Soliris, 2007.
  • Ultomiris, Soliris, Strensiq, and Koselugo span hematology, nephrology, endocrinology, and oncology-adjacent rare diseases.
  • AstraZeneca's 2021 acquisition gives Alexion global commercialization scale and deeper trial funding.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Flexible Work Hours
  • Remote Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
PR Newswire
Aug 23rd, 2024
Global Genes' Annual Week In Rare Event Heading To Kansas City

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."

StartupTicker
Apr 9th, 2024
Clinical Success For Neurimmune

Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases, has, in collaboration with its partner Alexion, advanced its drug candidate ALXN2220 into phase 3. This marks a significant step in the company’s journey to addressing the serious clinical condition ATTR-CM.  Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed, systemic clinical condition that leads to progressive heart failure and high rate of fatality within four years from diagnosis. Despite recent advances in slowing disease progression, there is currently no treatment available to deplete cardiac ATTR amyloid and revert cardiac dysfunction. Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia and ATTR cardiomyopathy, is currently testing a drug candidate, ALXN2220 (formerly NI006), a human antibody targeting ATTR Cardiomyopathy. In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, for ALXN2220. Neurimmune is responsible for completion of the phase 1b clinical study on behalf of Alexion, with Alexion incurring certain trial costs. Aside from the phase 1b trial, Alexion is responsible for further clinical development, manufacturing, and commercialization as ALXN2220. The two companies have now initiated the phase 3 of the DepleTTR-CM clinical study to assess the efficacy and safety of ALXN2220 for the treatment of ATTR-CM

Business Wire
Apr 1st, 2024
Voydeya™ Approved In The Us As Add-On Therapy To Ravulizumab Or Eculizumab For Treatment Of Extravascular Hemolysis In Adults With The Rare Disease Pnh

WILMINGTON, Del.--(BUSINESS WIRE)--VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).1 VOYDEYA is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant EVH while treated with a C5 inhibitor.2,3. The approval by the US Food and Drug Administration (FDA) was based on positive results from the pivotal ALPHA Phase III trial. Results from the 12-week primary evaluation period of the trial were published in The Lancet Haematology.2. Bart Scott, MD, Professor, Division of Hematology and Oncology at the University of Washington Medical Center, and Professor, Clinical Research Division at Fred Hutchinson Cancer Center, said: “The approval of VOYDEYA offers this small subset of PNH patients an add-on therapy designed to address EVH, while maintaining disease control with ULTOMIRIS or SOLIRIS. Terminal complement inhibition with ULTOMIRIS can address the life-threatening complications of PNH, building on the efficacy and safety of SOLIRIS established over nearly 20 years.”

Business Wire
Mar 25th, 2024
Ultomiris® (Ravulizumab-Cwvz) Approved In The Us For The Treatment Of Adults With Neuromyelitis Optica Spectrum Disorder (Nmosd)

WILMINGTON, Del.--(BUSINESS WIRE)--ULTOMIRIS® (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).1. The approval by the US Food and Drug Administration (FDA) was based on positive results from the CHAMPION-NMOSD Phase III trial, which were published in the Annals of Neurology.2 In the trial, ULTOMIRIS was compared to an external placebo arm from the pivotal SOLIRIS® PREVENT clinical trial. ULTOMIRIS met the primary endpoint of time to first on-trial relapse as confirmed by an independent adjudication committee. Zero relapses were observed among ULTOMIRIS patients with a median treatment duration of 73 weeks (relapse risk reduction: 98.6%, hazard ratio (95% CI): 0.014 (0.000, 0.103), p0.0001).2

PharmiWeb
Nov 28th, 2023
Nice Endorses Only Approved Treatment For Ultra-Rare Wolman Disease For Children Diagnosed Under The Age Of Two: Interview Opportunity

Sebelipase alfa (Kanuma®▼) recommended by NICE as the first treatment for infants with ultra-rare Wolman Disease.  . Kanuma, an enzyme replacement therapy, is the first medicine to be recommended for this life-threatening condition in infants under two years old